Phase II study on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by placement of 4Fr prophylactic pancreatic duct stent in patients who is performed endoscopic pancreatic duct injection (multicenter study)

Phase II study on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by placement of 4Fr prophylactic pancreatic duct stent in patients who is performed endoscopic pancreatic duct injection (multicenter study) - prevention of post-ERCP pancreatitis by placement of 4Fr prophylactic pancreatic duct stent

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031972

Enrollment

250

Registered

2018-03-29

Start date

2018-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biliary duct disease

Interventions

4Fr placement of prophylatic pancreatic duct stent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: .native papilla .patient who is performed endoscopic retrograde cholangiography purposes only in the biliary duct

Exclusion criteria

Exclusion criteria: .acute pancreatitis .postoperative reconstructed intestinal tract (Billroth ii, Roux-en-Y method) .patient with serious systemic illness, dangerous condition of life .intraductal papillary mucinous neoplasm .complete obstruction of main pancreatic duct .patient who already registered in this study once

Design outcomes

Primary

Measure	Time frame
frquency of post-endoscopic retrograde cholangiopancreatography pancreatitis	—

Countries

Japan

Contacts

Public ContactTakashi Tamura

Wakayama Medical University Second Department of Internal Medicine

ttakashi@wakayama-med.ac.jp073-447-2300

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026